Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03823911 · ClinicalTrials.gov registry record · Phase 4
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
A Phase 4 study of HIV and Cardiovascular Diseases, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
- 2
- Study locations
NCT03823911: Completed Phase 4 study of HIV and Cardiovascular Diseases, sponsored by University of Maryland, Baltimore.
NCT03823911 is a Phase 4 study of HIV and Cardiovascular Diseases that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 87 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03823911, a Phase 4 study of HIV and Cardiovascular Diseases, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and risk of cardiovascular disease.
Primary Outcome
Change in high-sensitivity C-reactive protein
Conditions Studied
Interventions
- PROCEDURE Cardiac MRI
- DRUG Elbasvir / Grazoprevir Oral Tablet [Zepatier]
Study Locations (2)
District of Columbia
- Unity Parkside Health Center - Washington D.C.
Maryland
- Institute of Human Virology, CRU - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-11-18 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 4 |
What the finished NCT03823911 record still lists
NCT03823911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Cardiac MRI is the first listed.
NCT03823911 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03823911 about?
NCT03823911 is a clinical study titled "Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication". This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls. This pilot study will demonstrate whether functional cure of HCV reduces myocardial injury and...
What is the current status of trial NCT03823911?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2018-11-18. Estimated completion is 2022-12-31.
What conditions does trial NCT03823911 study?
This clinical trial studies the following conditions: HIV, Cardiovascular Diseases, Hepatitis C.
What interventions are being tested in trial NCT03823911?
The interventions under investigation include: Cardiac MRI (PROCEDURE), Elbasvir / Grazoprevir Oral Tablet [Zepatier] (DRUG).
Who is sponsoring clinical trial NCT03823911?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03823911 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03823911's enrollment target sits among peer trials
87 169th of 303 higher than 135 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RECRUITING · Phase 4
-
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI